Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 24, 2004. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 900,000 ordinary shares of 25 pence each.
- Purchase Price: 1,133.8257 pence per share.
- Treasury Holdings: 54,928,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,881,958,449 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program authorized by shareholders at the Annual General Meeting on May 17, 2004. The company executed this purchase on November 24, 2004, increasing its Treasury share count.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 900,000 share repurchase based on the disclosed price of 1,133.8257 pence.
- Confirm the updated total share count and Treasury holdings against subsequent filings.
- Review the original shareholder authorization from the May 17, 2004 Annual General Meeting for remaining buyback limits.